The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
sandoz plans four biosimilar launches and reports significant sales growth
Sandoz, a global leader in generic and biosimilar medicines, reported over 30% sales growth in the first nine months of 2024, driven by its industry-leading pipeline of 28 biosimilars. The company plans to launch four biosimilars in 2025 and aims to capitalize on a significant market opportunity with over USD 400 billion in reference medicines losing exclusivity from 2029 to 2034. Sandoz is strategically positioned to enhance its market presence, particularly in the US biosimilars sector.
Sandoz settles US antitrust litigation for 275 million dollars
Sandoz has entered a settlement agreement for USD 275 million with the end payer plaintiffs in the US Generic Drug Antitrust Class Action Litigation, resolving claims from 2009 to 2019 without admitting wrongdoing. A provision of USD 265 million has also been set aside for outstanding claims, with no impact on the company's 2024 guidance. The settlement is subject to court approval, and Sandoz continues to defend against remaining antitrust claims.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.